prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Advanced prostate cancer in combination w/ LHRH analogue therapy or surgical castration.

Indication: Palliative treatment of hormone-dependent advanced prostate cancer. High-risk localized & locally advanced...

Indication: Adult men w/ metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after ...

Indication: In combination w/ prednisone or prednisolone for treatment of: metastatic castration resistant prostate cancer...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Monotherapy or in combination w/ other chemotherapeutic agents for metastatic non-seminomatous germ cell carci...

Indication: Monotherapy or combination therapy for palliative treatment of metastatic non-seminomatous germ cell carcinoma...

Indication: Locally advanced or metastatic prostate cancer. Genital & extragenital stage I-IV endometriosis. Precociou...

Indication: Breast, gastric, ovarian & small cell lung cancer; non-Hodgkin's lymphoma; advanced/metastatic soft tissue...

1  /  6
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 2 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.
3 days ago
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.